Logo of Clarity Pharmaceuticals (ASX:CU6)Latest Clarity Pharmaceuticals (ASX:CU6) News

Page 1
Page 1 of 5

Clarity Completes AMPLIFY Follow-Up Ahead of 2027 Prostate Cancer Data

Clarity Pharmaceuticals has completed final follow-up assessments for every participant in its registrational Phase III AMPLIFY trial of 64Cu-SAR-bisPSMA. Topline results from AMPLIFY and the related CLARIFY trial are expected in the first half of 2027, with the data intended to support US FDA applications.
Victor Sage
19 Nov 2026

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Clarity Completes 383-Patient Phase III Trial Ahead of 2027 Prostate Cancer Readout

Clarity Pharmaceuticals has completed planned recruitment for its 383-participant CLARIFY Phase III trial of 64Cu-SAR-bisPSMA, moving the diagnostic candidate into patient follow-up. Topline sensitivity and specificity data are expected in the first half of 2027 and could support a US FDA application.
Ada Torres
27 Oct 2026

Clarity Pharmaceuticals Nears US Readouts With $178.3 Million and Seven Therapy Responses

Clarity Pharmaceuticals is approaching pivotal Phase III readouts for its prostate cancer imaging agent, backed by AUD178.3 million in liquid assets. The radiopharmaceutical developer remains deeply loss-making, but expanded manufacturing capacity and early clinical signals are pulling its commercial ambitions into sharper focus.
Victor Sage
30 Sept 2026

Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.
Logan Eniac
29 Aug 2026

Clarity Pharmaceuticals Advances Clinical Trials Amid Rising Losses and Strong Cash Position

Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.
Ada Torres
27 Aug 2026

Market Wrap - Week 32 (3 Aug -> 7 Aug) 2026

Small-cap resources stocks led the week, while takeover activity and strong company results added to the gains. Wellnex Life more than doubled, but sharp falls in Trek Metals and Ionic Rare Earths showed that positive news did not always bring buyers.
Logan Eniac
8 Aug 2026

Healthcare Wrap - Week 32 (3 Aug -> 7 Aug) 2026

Wellnex led the healthcare market after agreeing to sell Pain Away for up to A$21.3 million. Neuren and Lumos also rose strongly as sales, royalties and product orders improved.
Logan Eniac
8 Aug 2026

Clarity Pharmaceuticals Unveils Superior Prostate Cancer Imaging and Therapy Data

Clarity Pharmaceuticals has presented compelling clinical evidence that its investigational 64Cu-SAR-bisPSMA diagnostic and 67Cu-SAR-bisPSMA therapeutic candidates outperform current standards in prostate cancer care, positioning the company for regulatory and commercial milestones.
Ada Torres
6 Aug 2026

Clarity Reports Promising Efficacy at 8 GBq Dose in Prostate Cancer Trial

Clarity Pharmaceuticals reveals encouraging early results from the SECuRE trial, with substantial PSA reductions and multiple complete responses at the 8 GBq 67Cu-SAR-bisPSMA dose level in advanced prostate cancer patients.
Ada Torres
5 Aug 2026

Market Wrap - Week 31 (27 July -> 31 July) 2026

Small-cap shares produced the week’s biggest moves, led by Xenitra’s 60% surge and Carnaby Resources’ takeover jump.
Mining news dominated, but sharp falls in Lotus Resources and several funded developers showed that new capital can still unsettle investors.
Logan Eniac
1 Aug 2026

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.
Logan Eniac
1 Aug 2026